Kazia Therapeutics annual return on equity
2017
2018
2019
2020
2021
2022
2023
2024
Kazia Therapeutics Return on Equity (ROE) Growth & History (KZIA)
Kazia Therapeutics's return on equity was −2,634.33% for fiscal 2024.
View full Kazia Therapeutics company overviewKazia Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-06-30 | −2,634.33% | −2499.36 pp |
| 2023 | 2023-06-30 | −134.97% | −45.84 pp |
| 2022 | 2022-06-30 | −89.14% | −56.74 pp |
| 2021 | 2021-06-30 | −32.40% | +55.64 pp |
| 2020 | 2020-06-30 | −88.04% | −26.61 pp |
| 2019 | 2019-06-30 | −61.43% | −34.34 pp |
| 2018 | 2018-06-30 | −27.09% | +8.91 pp |
| 2017 | 2017-06-30 | −36.01% | — |
Kazia Therapeutics return on equity trends
Over the last five fiscal years, Kazia Therapeutics's return on equity decreased from −61.43% to −2,634.33%, a change of −2572.90 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kazia Therapeutics source filings ↗